Teva/Ivax Deal
This article was originally published in The Tan Sheet
Executive Summary
Teva Pharmaceuticals' acquisition of fellow generics firm Ivax is expected to close on Jan. 12, 2006, the firms state in a joint release Dec. 23. The Israeli firm Teva and the Miami, Fla.-based Ivax have now signed a consent order for submission to FTC, which is "the last remaining regulatory condition to the consummation of the transaction," the release states. The deal cannot close until FTC approves a consent order, they note. The planned acquisition was announced in July 2005 ("The Tan Sheet" Aug. 1, 2005, p. 11)...
You may also be interested in...
Teva Broadens Private Label OTC Offerings With Ivax Acquisition
Teva's planned acquisition of Ivax adds a wide range of private label OTCs to the firm's generic drug portfolio
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.